Urinary Retention Clinical Trials 2023

What are the top hospitals conducting urinary retention research?

When it comes to advancing the understanding and treatment of urinary retention, several top hospitals are leading the way. The University of Michigan in Ann Arbor is currently conducting two active clinical trials focused on urinary retention. Since recording its first trial in 2020, this institution has shown a commitment to investigating innovative approaches for this condition. Similarly, Cleveland Clinic Florida in Weston is also actively involved with two ongoing urinary retention trials and has completed three previous studies since initiating their research efforts back in 2015.

In Pittsburgh, West Penn Hospital is making significant contributions as well, currently participating in two active urinary retention trials while having conducted an additional two studies previously since starting their investigations in 2019.

Meanwhile, the University of Texas at Austin's Dell Seton Medical Center and Seton Medical Center Austin are both dedicated to furthering knowledge about urinary retention with one current trial each. Although they have recently entered into the field by recording their inaugural research efforts set for 2023; these institutions demonstrate promising potential for breakthroughs.

Urinary retention can be a distressing condition that affects individuals' quality of life and overall health. These hospitals' dedication to studying various aspects of this condition brings hope to those suffering from it worldwide. By exploring new treatments and interventions through rigorous clinical trials, these institutions play a vital role in improving patient outcomes and paving the path toward enhanced care strategies for urinary retention patients everywhere

Which are the best cities for urinary retention clinical trials?

When it comes to urinary retention clinical trials, several cities show promise as leading hubs of research and development. Cincinnati, Ohio takes the lead with four active trials investigating treatments like integrated care pathways and Peppermint oil vapors. Following closely behind are Austin, Texas and New Orleans, Louisiana, both hosting three ongoing studies exploring innovative approaches such as catheter self-discontinuation group and sacral neuromodulation. Additionally, Pittsburgh, Pennsylvania contributes significantly to the field with three active trials focused on interventions like superficial peroneal nerve stimulation and lidocaine with epinephrine. While Dallas, Texas also makes a notable contribution with two ongoing trials investigating treatments such as neostigmine. These cities offer individuals experiencing urinary retention access to cutting-edge clinical trials that pave the way for advancements in care and potential improvements in quality of life.

Which are the top treatments for urinary retention being explored in clinical trials?

Urinary retention is a challenging condition, but ongoing clinical trials are exploring potential treatments to provide relief. Among the top contenders are:

• Medtronic Interstim II Model 3058 Neurostimulator: This device is currently being tested in two active trials for urinary retention. It has also been involved in two historic trials since its listing in 2020.

• Neostigmine: Another promising option, neostigmine is part of two ongoing clinical trials for urinary retention. Its first listing was recorded in 2023.

• Tamsulosin: With two active trials and a total of 18 historical urinary retention studies since it was introduced in 2007, tamsulosin continues to be explored as an effective treatment option.

• Sugammadex: A newcomer on the scene, sugammadex has shown promise with its participation in five all-time urinary retention trials so far. It made its debut into research listings in 2022.

These treatments hold hope for individuals suffering from this distressing condition and may offer new solutions for managing and treating urinary retention moving forward.

What are the most recent clinical trials for urinary retention?

Recent clinical trials have offered new insights and potential treatments for urinary retention, a condition that can greatly impact quality of life. One notable trial investigated the use of Tamsulosin, an alpha-blocker medication, in a Phase 3 study. Preliminary results indicate its effectiveness in relieving urinary retention symptoms. Sugammadex also shows promise as it undergoes both Phase 1 and Phase 2 trials to assess its efficacy in treating this condition. Additionally, Neostigmine is being evaluated in a Phase 4 trial to determine its benefits for individuals experiencing urinary retention. These ongoing studies provide hope for improved management and relief from urinary retention symptoms.

What urinary retention clinical trials were recently completed?

The University of Arizona recently completed a clinical trial investigating the efficacy and safety of Tamsulosin in treating urinary retention. This study, which concluded in April 2021, sought to provide valuable insights into the potential benefits of this medication for individuals with urinary retention. The completion of this trial represents an important step forward in understanding how to effectively manage this condition and improve patients' quality of life.